DCP1A and osteosarcoma: In that experiment, we used DCP1A as a PB marker(Rzeczkowski et al., 2011) and treated U2OS cells (a human osteosarcoma epithelial cell line) with 2 mM Leu-Leu-O-Me (LLOMe), a well-characterized lysosome-damaging agent(Thiele et al., 1990), for 30 min.